Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Mycovia, a biopharmaceutical company, released topline results from evaluating VIVJOA™ (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC).
Also known as chronic yeast infection, RVVC is a distinct condition from vulvovaginal candidiasis (VVC) and is defined by the Centers for Disease Control and ...
read more
Boehringer Ingelheim Animal Health announced that the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) has granted conditional approval of VETMEDIN®-CA1 (pimobendan), which is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD), a form of ...
read more
Preliminary results of 60 Degrees Pharma’s phase II study of ARAKODA® (tafenoquine) for treatment of mild-moderate COVID-19 disease have been published in the peer-reviewed journal, New Microbes and New Infections.
read more
ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets.
read more
Apotex Inc., a Canadian pharmaceutical manufacturer of generic medicines, announced the launch of APO-ApixabanTM tablets, Canada's first generic alternative to Eliquis®.
read more
Exelixis announced the initiation of STELLAR-303, a phase 3 trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy. XL092 is a ...
read more
Cremer, a supplier of product counting machines in the U.S., has introduced its HQS 1250 Counting & Dispensing Machine, designed specifically for gummy applications in the nutraceutical and confectionary sectors.
read more
The global Bone & Joint Health Supplements Market is estimated to be valued at $11.7B in 2022, according to a report by MarketsandMarkets™. It is projected to reach $17.6B by 2027, recording a CAGR of 8.5% during the forecast period.
read more
Tablet coating prices are projected to rise by 2-5% by 2026, according to a report by SpendEdge. The Tablet Coatings Market is expected to have a CAGR of 4.50% during 2022-2026.
read more
The global generic pharmaceuticals market is expected to grow from $302.39B in 2021 to $332.43B in 2022 at a compound annual growth rate (CAGR) of 9.9%. The market is expected to reach $426.30B in 2026 at a CAGR of 6.4%, according to a report by Research & Markets.
read more
ACG, a supplier of integrated manufacturing equipment to the global pharmaceutical and nutraceutical industries, appointed Gerd Hueffmann as the new head of global sales and commercial excellence for ACG Engineering.
read more
Increasing number of inorganic growth strategies by market key players is expected to drive the growth of global sustained release coating market during the forecast period.
read more
The global blister packaging market has been growing at a fast rate and is projected to reach$ 22.9B by 2031, with an increase from the pharmaceutical sector creating massive demand for these types of products in particular.
read more
Prothione LLC, a U.S. based pharmaceutical company announced results from a Phase II trial of Prothione capsules for the treatment of mild to moderate COVID-19. The data show that patients assigned treatment with the drug had a reduction in time to clinical resolution as defined by the time to attain 3 consecutive negative RT-PCR tests and a ...
read more
Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.
read more